Press Releases

Exploratory data presented for Active Biotech's ANYARA project
February 10, 2010 20:02 (CET)
TEVA ACQUIRES MARKETING RIGHTS FOR ORAL LAQUINIMOD IN THE NORDIC AND BALTIC REGIONS
February 8, 2010 14:30 (CET)
Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial in prostate cancer patients
December 14, 2009 08:30 (CET)
Active Biotech AB Interim Report, January - September 2009
November 5, 2009 08:30 (CET)
Active Biotech's election committee appointed
November 5, 2009 08:30 (CET)
RhuDex Clinical Development to Continue Following Feedback from Regulatory Authorities
October 5, 2009 11:30 (CEST)
Active Biotech's Prostate Cancer Project TASQ Featured in British Journal of Cancer
September 25, 2009 08:30 (CEST)
Active Biotech to Present at the UBS Global Life Sciences Conference
September 17, 2009 14:00 (CEST)
LAQUINIMOD IMMUNOMODULATORY ACTION CONFERS BOTH NEUROPROTECTIVE AND ANTI-INFLAMMATORY PROPERTIES
September 11, 2009 15:30 (CEST)
Laquinimod presentations at ECTRIMS
September 8, 2009 16:16 (CEST)